NO20000996D0 - Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel - Google Patents

Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel

Info

Publication number: NO20000996D0
Authority: NO; Norway
Prior art keywords: atorvastatin; combination therapy; antihypertensive agent; antihypertensive; agent
Prior art date: 1997-08-29

Application number

NO20000996A

Other languages

English (en)

Other versions

NO323987B1 (no

NO20000996L (no

Inventor

Robert Andrew Donald Scott

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-29

Filing date

2000-02-28

Publication date

2000-02-28

2000-02-28 Application filed by Pfizer filed Critical Pfizer

2000-02-28 Publication of NO20000996D0 publication Critical patent/NO20000996D0/no

2000-04-27 Publication of NO20000996L publication Critical patent/NO20000996L/no

2007-07-30 Publication of NO323987B1 publication Critical patent/NO323987B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Pyrrole Compounds (AREA)

NO20000996A 1997-08-29 2000-02-28 Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett NO323987B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5727697P	1997-08-29	1997-08-29
PCT/IB1998/001230 WO1999011260A1 (en)	1997-08-29	1998-08-11	Combination therapy comprising atorvastatin and an antihypertensive agent

Publications (3)

Publication Number	Publication Date
NO20000996D0 true NO20000996D0 (no)	2000-02-28
NO20000996L NO20000996L (no)	2000-04-27
NO323987B1 NO323987B1 (no)	2007-07-30

Family

ID=22009602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000996A NO323987B1 (no)	1997-08-29	2000-02-28	Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett

Country Status (41)

Country	Link
US (2)	US20020099046A1 (no)
EP (1)	EP1009400B1 (no)
JP (2)	JP2001514223A (no)
KR (3)	KR20040106591A (no)
CN (3)	CN1473566A (no)
AP (1)	AP1191A (no)
AR (1)	AR016399A1 (no)
AT (1)	ATE285767T1 (no)
AU (1)	AU740424B2 (no)
BG (1)	BG64724B1 (no)
BR (1)	BR9811556A (no)
CA (1)	CA2296723A1 (no)
CO (1)	CO4970724A1 (no)
DE (1)	DE69828413T2 (no)
DZ (1)	DZ2595A1 (no)
EA (1)	EA200000012A1 (no)
EG (1)	EG24678A (no)
ES (1)	ES2234134T3 (no)
GT (1)	GT199800126A (no)
HR (1)	HRP980474A2 (no)
HU (1)	HUP0004318A3 (no)
ID (1)	ID24118A (no)
IL (2)	IL133962A0 (no)
IS (1)	IS5341A (no)
MA (1)	MA26536A1 (no)
MY (1)	MY121008A (no)
NO (1)	NO323987B1 (no)
NZ (2)	NZ530630A (no)
OA (1)	OA11291A (no)
PA (1)	PA8457901A1 (no)
PE (1)	PE107099A1 (no)
PL (1)	PL339091A1 (no)
PT (1)	PT1009400E (no)
SA (1)	SA98190603B1 (no)
SK (1)	SK1432000A3 (no)
TN (1)	TNSN98155A1 (no)
TR (1)	TR200000563T2 (no)
UY (1)	UY25155A1 (no)
WO (1)	WO1999011260A1 (no)
YU (1)	YU2000A (no)
ZA (1)	ZA987839B (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9306393A (pt)	1992-05-19	1998-09-15	Graham Edmund Kelly	Suplemento natural e processo para melhorar a saúde de um ser humano
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en)	1996-08-30	1996-09-26	Novogen Research Pty Ltd	Therapeutic uses
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
EP1063991A1 (en) *	1998-03-17	2001-01-03	Warner-Lambert Company Llc	Statin-matrix metalloproteinase inhibitor combinations
US6489366B1 (en)	1998-12-23	2002-12-03	G. D. Searle, Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
NZ517468A (en)	1999-08-30	2004-02-27	Aventis Pharma Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AUPQ266199A0 (en)	1999-09-06	1999-09-30	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) *	1999-09-20	2001-03-29	Bayer Ag	Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1218017B1 (en)	1999-09-24	2005-11-16	Vasogen Ireland Limited	Combination of a statin and ex-vivo treated blood for treating atherosclerosis
FR2803525B1 (fr) *	2000-01-06	2002-05-03	Sod Conseils Rech Applic	Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) *	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en)	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) *	2000-06-22	2000-06-22	Astrazeneca Ab	New formulation
SK287558B6 (sk)	2000-07-19	2011-02-04	Novartis Ag	Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli
EP1314425A4 (en) *	2000-08-30	2004-06-02	Sankyo Co	MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7018649B2 (en) *	2000-10-23	2006-03-28	Euro-Celtique, S.A.	Felodipine transdermal device and methods
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) *	2001-01-16	2001-02-08	Novogen Research Pty Ltd	Regulation of lipids and/or bone density and compositions therefor
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1413331B1 (en)	2001-01-26	2007-10-03	Schering Corporation	Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications
MY138301A (en)	2001-01-26	2009-05-29	Schering Corp	The use of substituted azetidinone compounds for the treatment of sitosterolemia
AUPR363301A0 (en)	2001-03-08	2001-04-05	Novogen Research Pty Ltd	Dimeric isoflavones
AP2004002951A0 (en) *	2001-07-19	2004-03-31	Pharmacia Corp	"Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) *	2001-08-06	2005-02-08	Recordati Ireland Limited	Crude and crystalline forms of lercanidipine hydrochloride
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en)	2001-09-21	2006-08-24	Merck Sharp & Dohme Corp.	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA04006255A (es)	2002-01-17	2004-09-27	Pharmacia Corp	Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
ES2304521T3 (es) *	2002-06-20	2008-10-16	The Governors Of The University Of Alberta	Dicloroacetato en combinacion con farmacos cardioprotectores o hemodinamicos.
AU2003248746B2 (en) *	2002-06-27	2009-01-08	Smithkline Beecham (Cork) Limited	Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
CA2492084A1 (en) *	2002-06-27	2004-01-08	Sb Pharmco Puerto Rico Inc.	Carvedilol hydobromide
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) *	2002-10-16	2006-02-09	レコーダチアイルランドリミテッド	リシノプリル／レルカニジピンの組み合わせ治療
JP2006508188A (ja)	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
WO2004081003A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7235543B2 (en)	2003-03-07	2007-06-26	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es)	2003-03-07	2005-10-18	Schering Corp	Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
JP2007512350A (ja) *	2003-11-25	2007-05-17	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	カルベジロール組成物の治療および送達方法
EP1691789B1 (en) *	2003-11-25	2017-12-20	SmithKline Beecham (Cork) Limited	Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051383A1 (en) *	2003-11-25	2005-06-09	Sb Pharmco Puerto Rico Inc.	Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
KR20050092519A (ko) *	2004-03-16	2005-09-22	화이자 인코포레이티드	아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
US20070191438A1 (en) *	2004-04-06	2007-08-16	Rohrer Susan P	Methods for the treatment of hypertension
JP4880591B2 (ja)	2004-06-04	2012-02-22	テバファーマシューティカルインダストリーズリミティド	イルベサルタンを含む医薬組成物
WO2006026469A2 (en) *	2004-08-25	2006-03-09	Essentialis, Inc.	Pharmaceutical formulations of potassium atp channel openers and uses thereof
MX2007009779A (es) *	2005-02-17	2007-09-26	Chiesi Farma Spa	Combinaciones terapeuticas de manidipina y una estatina.
US8124622B2 (en) *	2006-03-29	2012-02-28	Kowa Co., Ltd.	Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
EP2086519B1 (en) *	2006-10-30	2017-06-21	HanAll Biopharma Co., Ltd.	Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2009134057A2 (ko)	2008-04-29	2009-11-05	한올제약주식회사	안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CZ301299B6 (cs) *	2008-11-24	2010-01-06	Zentiva, A.S.	Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
ES2580777T3 (es) *	2009-01-23	2016-08-26	Hanmi Holdings Co., Ltd.	Composición farmacéutica sólida que comprende amlodipino y losartán y procedimiento para producir la misma
SI23149A (sl) *	2009-09-21	2011-03-31	Silverstone Pharma	Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) *	2011-10-27	2013-05-10	Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ"	Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) *	2011-12-17	2012-09-19	东莞达信生物技术有限公司	一种降压降脂复方药及其制备方法
KR20140028971A (ko) *	2012-08-31	2014-03-10	한미약품 주식회사	아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
EP2977048A4 (en) *	2013-03-12	2017-04-26	LG Life Sciences Ltd.	Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN104173420A (zh) *	2013-05-20	2014-12-03	广州诺氏刘生物科技有限公司	一种治疗急性肾衰竭的药物
NZ731751A (en)	2014-10-23	2023-07-28	Arena Pharm Inc	Method of treating conditions related to the pgi2 receptor
MX382254B (es) *	2015-06-30	2025-03-13	Hanmi Pharmaceutical Co Ltd	Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
FR3040303B1 (fr) *	2015-08-27	2019-04-05	Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger	Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) *	2015-11-19	2016-01-13	哈尔滨圣吉药业股份有限公司	一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
US20200315233A1 (en) *	2016-06-02	2020-10-08	Ana Pharmaceuticals, Inc.	Methods and compositions for treatment of hypercalciuria and nephrolithiasis
HRP20240701T1 (hr)	2017-01-25	2024-09-27	The George Institute for Global Health	Pripravci za uporabu u liječenju hipertenzije
EP3977985B1 (en)	2017-03-01	2023-09-06	Arena Pharmaceuticals, Inc.	Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
WO2019222764A1 (en)	2018-05-16	2019-11-21	Arena Pharmaceuticals, Inc.	Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR20210038931A (ko) *	2018-07-26	2021-04-08	더 조지 인스티튜트 포 글로벌 헬스	고혈압 치료용 조성물
CN112826937B (zh) *	2021-03-25	2022-03-22	山东大学齐鲁医院	艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4681893A (en) *	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) *	1994-08-24	1995-09-05	Bristol-Myers Squibb Company	α-phosphonosulfinic squalene synthetase inhibitors
RU2158607C2 (ru) *	1995-07-03	2000-11-10	Санкио Компани Лимитед	Лечение артериосклероза и ксантомы
AU720853B2 (en) *	1995-11-02	2000-06-15	Warner-Lambert Company	Method and pharmaceutical composition for regulating lipid concentration

1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 CA CA002296723A patent/CA2296723A1/en not_active Abandoned
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 EP EP98935250A patent/EP1009400B1/en not_active Expired - Lifetime
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/en active Application Filing
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/xx active
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MA26536A1 (fr)	2004-12-20
GT199800126A (es)	2000-01-29
PE107099A1 (es)	1999-11-06
YU2000A (sh)	2002-12-10
KR20040106591A (ko)	2004-12-17
EP1009400B1 (en)	2004-12-29
HUP0004318A3 (en)	2002-10-28
NO323987B1 (no)	2007-07-30
US20020099046A1 (en)	2002-07-25
ID24118A (id)	2000-07-06
ZA987839B (en)	2000-02-28
NO20000996L (no)	2000-04-27
CA2296723A1 (en)	1999-03-11
AP1191A (en)	2003-07-19
TNSN98155A1 (fr)	2005-03-15
DZ2595A1 (fr)	2003-02-22
DE69828413T2 (de)	2005-12-08
IS5341A (is)	2000-01-14
CN1473567A (zh)	2004-02-11
JP2005041875A (ja)	2005-02-17
PT1009400E (pt)	2005-02-28
PL339091A1 (en)	2000-12-04
AU8458998A (en)	1999-03-22
AP9801332A0 (en)	1998-09-30
AR016399A1 (es)	2001-07-04
HRP980474A2 (en)	1999-06-30
CO4970724A1 (es)	2000-11-07
US20030199492A1 (en)	2003-10-23
NZ530630A (en)	2005-05-27
KR20010022477A (ko)	2001-03-15
CN1268053A (zh)	2000-09-27
DE69828413D1 (de)	2005-02-03
EA200000012A1 (ru)	2000-08-28
WO1999011260A1 (en)	1999-03-11
IL133962A (en)	2006-07-05
IL133962A0 (en)	2001-04-30
PA8457901A1 (es)	2000-05-24
BG104075A (en)	2000-09-29
BG64724B1 (bg)	2006-01-31
NZ502280A (en)	2002-11-26
JP2001514223A (ja)	2001-09-11
HUP0004318A2 (hu)	2001-05-28
SK1432000A3 (en)	2000-12-11
EG24678A (en)	2010-04-27
CN1473566A (zh)	2004-02-11
EP1009400A1 (en)	2000-06-21
MY121008A (en)	2005-12-30
UY25155A1 (es)	2000-12-29
SA98190603B1 (ar)	2006-07-04
ES2234134T3 (es)	2005-06-16
BR9811556A (pt)	2000-08-22
OA11291A (en)	2003-08-25
TR200000563T2 (tr)	2000-07-21
AU740424B2 (en)	2001-11-01
ATE285767T1 (de)	2005-01-15
KR20030015394A (ko)	2003-02-20

Publication	Publication Date	Title
NO20000996L (no)	2000-04-27	Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel
DK1454907T3 (da)	2009-03-09	Quninazolin og pyridopyrmidin-derivativer
IS5525A (is)	2000-06-08	Innúðabúnaður og aðferð
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
NO991150L (no)	1999-09-13	Pyrazolopyrimidiner og pyrazolotriaziner
DK1041879T3 (da)	2008-04-14	Desinfektionsmiddel og fremstillingsmetode
NO20011821D0 (no)	2001-04-10	Arbeidsromorganisering og möbelsystem
CY2007003I1 (el)	2009-11-04	Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη
DK0915880T3 (da)	2008-02-11	Azolotriaziner og pyrimidiner
IS4481A (is)	1997-05-12	Díhýdrópyramídín og notkun þeirra
NO991151D0 (no)	1999-03-10	Forbindelse og anvendelse derav
NO991286D0 (no)	1999-03-17	Labyrintpakning og monteringsfremgangsmÕte
NO20001323D0 (no)	2000-03-14	Dipeptid-apoptose inhibitorer og deres anvendelse
NO991701D0 (no)	1999-04-09	HIV og cancer behandling
ID24275A (id)	2000-07-13	Terapi kombinasi
DE69836008D1 (de)	2006-11-09	Zusammensetzung und behandlungsmittel
NO983576L (no)	1999-02-08	Br°nnbehandlingsfluider og fremgangsmÕter
DK0906301T3 (da)	2003-02-10	Benzofurylderivater og anvendelsen deraf
NO20006488D0 (no)	2000-12-19	Sammensetning og anvendelse
NO20002387L (no)	2000-06-05	FremgangsmÕter og systemer ved applikasjonsomslag
NO972206D0 (no)	1997-05-13	Bjelke og karosserikonstruksjon
NO964541L (no)	1996-12-23	Porphacyanin og CNC-utvidete porphyriner
NO20012738D0 (no)	2001-06-01	Terapeutiske produkter og anvendelse derav
DK1140952T3 (da)	2004-01-12	Phosphororganiske forbindelser og anvendelse heraf
NO984921D0 (no)	1998-10-22	Tienopyridinderivater og deres anvendelse